Orlifit 120 mg (Capsule)
Unit Price: ৳ 50.00 (2 x 6: ৳ 600.00)
Strip Price: ৳ 300.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Orlistat |
| Company | Opsonin pharma ltd |
Indications
- Treatment of obese patients with BMI >30 kg/m2
- Treatment of overweight patients with BMI >28 kg/m2 and associated risk factors
- Treatment of obese adolescents when other measures fail
Pharmacology
- Potent, specific and long-acting lipase inhibitor
- Forms covalent bond with active serine site of gastric and pancreatic lipases
- Inactivated enzyme unable to hydrolyze dietary fats into absorbable free fatty acids and monoglycerides
- Promotes caloric deficit leading to weight control
- Systemic absorption not needed for activity
- Inhibits dietary fat absorption by approximately 30% at recommended dose
Dosage & Administration
- Recommended dose of one 120 mg capsule with each main meal
- Omit dose if meal contains no fat or is missed
- No additional benefits shown with doses above 120 mg three times daily
- Increases fecal fat 24-48 hours after dosing
- Safety & efficacy studied in clinical studies lasting up to 4 years
- Same recommended dose for adolescents as for adults
- Special dosage instruction not studied in elderly patients or those with hepatic and/or renal impairments
Interaction
- Reduction in cyclosporine plasma levels when coadministered with Orlifit
- Inhibition of absorption of vitamin E acetate supplement
- Effect on absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K not known
- Reported hypothyroidism in patients treated concomitantly with Orlifit and levothyroxine
- Possible decreased vitamin K absorption with Orlifit
- Close monitoring recommended for patients on chronic stable doses of warfarin who are prescribed Orlifit
- Reported convulsions in patients treated concomitantly with antiepileptic drugs
Contraindications
- Chronic malabsorption syndrome
- Cholestasis
- Hypersensitivity to orlistat or other ingredients of the capsules
Side Effects
- Common gastrointestinal side effects such as oily spotting, flatulence, fecal urgency, oily or fatty stool, and abdominal discomfort
- Rare cases of influenza, anxiety, headache, fatigue, and hypersensitivity reported
Pregnancy & Lactation
- Contraindicated during pregnancy due to potential harm to the fetus
- Caution advised when administered to nursing women
Precautions & Warnings
- Organic causes of obesity should be excluded before prescribing Orlifit
- Coadministration with cyclosporine should be avoided
- Decrease in body weight may be less in type II diabetic patients
- Antidiabetic drug treatment should be closely monitored during Orlifit therapy
- Adherence to dietary recommendations and fat distribution advised
- Encouragement of multivitamin supplement intake recommended for fat soluble vitamins and beta-carotene
- Adjustment of oral antidiabetics or insulin may be necessary due to improvement in glycemic control
Overdose Effects
- Single doses of 800 mg and multiple doses of up to 400 mg three times a day for 15 days studied without significant adverse findings
- Observation recommended for 24 hours in case of significant overdose
Therapeutic Class
- Appetite suppressant drugs/Anti-obesity drugs
Storage Conditions
- Store below 30°C, protect from light & moisture
- Keep out of reach of children